Skip to main content

Lipodystrophy

1
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
tenofovir DFPhase 21 trial
Active Trials
NCT00647946Completed100Est. Feb 2006
Regeneron
RegeneronTARRYTOWN, NY
1 program
REGN4461N/A1 trial
Active Trials
NCT04710056Available
Bristol Myers Squibb
1 program
metreleptinN/A1 trial
Active Trials
NCT00677313Completed41Est. Jan 2015
Sanofi
SanofiPARIS, France
1 program
Sculptra InjectionPHASE_41 trial
Active Trials
NCT00360139Withdrawn15Est. Dec 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiSculptra Injection
Kite Pharmatenofovir DF
Bristol Myers Squibbmetreleptin

Clinical Trials (4)

Total enrollment: 156 patients across 4 trials

NCT00360139SanofiSculptra Injection

Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy

Est. completion: Dec 200815 patients
Phase 4Withdrawn

Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue

Start: Feb 2003Est. completion: Feb 2006100 patients
Phase 2Completed

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

N/AAvailable

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Start: Mar 2009Est. completion: Jan 201541 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.